The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning on the risk of severe liver injury with daclizumab.¹ The MHRA has advised that, while an urgent EU-wide review of new information on liver safety is under way, initiation of daclizumab in multiple sclerosis (MS) should be restricted to patients with limited treatment options. Prescribers should promptly review patients already on treatment to assess whether it continues to be appropriate for them. The review should include a discussion with …